To get Mounjaro (tirzepatide) on the NHS for weight loss, you need a BMI of 40 or more (adjusted for ethnicity) and a diagnosis of at least four of these conditions: Type 2 diabetes, high blood pressure, heart disease, obstructive sleep apnoea, or abnormal blood fats (dyslipidaemia).
Who is eligible?
- BMI: 40+ (or 37.5+ for Black, Asian, and other minority ethnic backgrounds).
- Co-morbidities: At least four of the following diagnosed conditions:
- Type 2 diabetes
- High blood pressure (hypertension)
- Heart disease (cardiovascular disease)
- Obstructive sleep apnoea (confirmed by study)
- Abnormal blood fats (dyslipidaemia)
If you think you may be eligible for this service, please contact the practice and ask to speak with our Care Coordinators.
They will review your records to confirm whether you meet the criteria. If you do, we will refer you to the Weight Management Service, who will initiate the medication.
Please Note:
- The practice does not start medication or monitor patients who are under Mounjaro.
- We do agree to shared care and will prescribe medication only when you are under the Weight Management Service.
If you would be interested in other weight loss management then there are several options
Tier 2 is self referral to https://www.yourhealthnorfolk.co.uk/weight-management where there are several options
Tier 3 is GP referral and the criteria is the following – if you fit the criteria then please book a routine appointment to discuss the referral with your usual GP
- Age: 18 years or over
- BMI & Co-morbidities:
- BMI of 40 or more.
- OR BMI of 35 or more plus significant weight-related conditions (e.g., Type 2 diabetes, severe sleep apnea, cardiovascular disease, PCOS).
- Previous Support: Often requires previous engagement with Tier 2 (community-based) weight management programs, showing need for more intensive help.
- Ethnicity: Lower BMI thresholds (e.g., 27.5+) may apply for Black, South Asian, or other ethnic minority groups due to higher risk.
- Motivation: Evidence of willingness to commit to significant lifestyle changes.
New Semaglutide (Wegovy) Tablet Approved – Not Available on the NHS
The MHRA has approved the first GLP‑1 tablet (semaglutide) for weight loss and weight management in the UK. This is a once‑daily tablet licensed for adults with obesity or those who are overweight with a weight‑related health condition.
At present, this medication is not available through the NHS, and GP practices cannot prescribe it. Please do not contact the practice to request a prescription, as we are unable to issue it.
Patients seeking support with weight management can discuss existing NHS‑approved options with our clinical team.